Discipline before instinct.
Think with me, not just trade with me.
No stock tips, no hype calls. Every judgment runs through the same repeatable process: first filter out what should never be touched, then decide how to enter and how to control risk. You see the conclusion — and every step of the reasoning.
Positioning, moat, volatility, technicals — filtered in order. First ask "should I touch this at all", then "how do I enter".
Institutional strength, relative strength and earnings quality quantified into a reviewable verdict — not a gut call.
Stock selection, options selling and financial-statement analysis — each track runs from concept to executable SOP.
Three Learning Tracks
Full curriculum →Stock selection, options selling, financial analysis. Each track goes from concepts and tools to executable SOPs.
Super Performance Stock Selection
Built on Mark Minervini’s SEPA methodology, integrating CANSLIM with technical entry execution — from why to buy strength to when to buy, sell, and how much.
Options Selling System
Probability-first: from seller philosophy and core tools to full strategy SOP and risk management — a cash-flow framework that puts time on your side.
Financial Statement Analysis
The intro track teaches you to read the three statements, footnotes and earnings calls; the advanced series teaches you to see through them — CPA audit lens, CFA quality frameworks, and AI-assisted screening.
This Week’s Screen Signals
Updated 2026-08-10Verdicts from the Four-Layer Defensive Screen, reasoning included.
Latest Research
Thematic ETFs: BOTZ / AIQ / CIBR / URA / PAVE — Getting the Theme Right Doesn't Mean Getting Paid
Robotics, AI, cyber, uranium, infrastructure — five thematic ETFs pass the screen, but URA is annualized at -2.55% over 15 years and BOTZ still lags the market even with a real Nvidia bet baked in. The theme playing out doesn't mean you got paid — three variables sit in between.
Biotech ETFs: XBI vs. IBB — Equal-Weight Innovation vs. Cap-Weighted Leaders
Biotech is a portfolio of binary events: FDA approval is the gate, and the PDUFA date is when the lottery is drawn. XBI equal-weights a bet on broad innovation; IBB cap-weights a bet on incumbent leaders. Neither logic is wrong — you're choosing which bet to make.
Datadog (DDOG) Q2 2026 Update: A Perfect Quarter, the Market Is Betting on One Customer
Revenue up 36% YoY, full-year guidance raised again — and the stock still dropped nearly 20% in a day on one AI-native customer's usage pullback. 750+ AI-native customers, non-AI revenue growth accelerating toward 30%, and four distinct AI/MCP product lines (LLM Observability, Agent Observability, Datadog MCP Server, Bits AI): concentration is being diluted, just not fast enough this quarter.
The Trade Desk (TTD) Q2 2026 Update: First-Ever Guided Revenue Decline, the AI Operating System Narrative Can’t Hold
Revenue growth cut to just 3% YoY, Q3 guidance implying a 12% decline — two of the three pillars behind March's rebound have broken. The Publicis billing audit, a nearly full C-suite turnover, and historical DSP-industry precedent (Rocket Fuel, Criteo, Meta) test whether the “open-internet AI advertising operating system” narrative still holds.